Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS trial_result · 2025-11-12

Clinical Trial Update: A Study of Imlunestrant (LY3484356) in Female Participants With Impaired Liver Function [Phase 1]

View source ↗

Summary

Phase 1 study evaluating Imlunestrant (LY3484356) in female participants with hepatic insufficiency, with results posted after completion.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • Imlunestrant (imlunestrant)

Snippet

Sponsor: Eli Lilly and Company | Conditions: Hepatic Insufficiency, Healthy | Phase 1 | Status: COMPLETED | Results posted: 2025-11-12